Casi Pharmaceuticals Inc (CASI) Stock Price, Quote & News

Company Profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investiga...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 10 6508 6063

Website: www.casipharmaceuticals.com

Address:

1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Chaoyang District, Beijing, China

BEATOFtheMARKET Jan. 12 at 7:49 PM

$CASI $DRTS $VNET $PYXS Cycle Trading Signal 🔥 app 🔥

0 · Reply

DARKP00L Jan. 12 at 2:18 PM

$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas

0 · Reply

DARKP00L Jan. 12 at 2:08 PM

$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas

0 · Reply

MrDaily Jan. 10 at 1:59 PM

$CASI after the reverse split you’d have to be insane to take a 1.15/share to sell this

0 · Reply

agamemnus Jan. 9 at 5:02 PM

$CASI $1.15 acquisition proposal by biggest shareholder. https://archive.fast-edgar.com/20260109/AUB2K22C8222P2Z2222I2MZZ5H92R2X2N282/

0 · Reply

V9RDPUMA Jan. 9 at 2:07 PM

$CASI Rare disease play

0 · Reply

ClassiTrader Jan. 9 at 12:11 AM

$CASI 💪

0 · Reply

JGroove Jan. 5 at 5:03 PM

$CASI when does the appeal expire?

1 · Reply

MarketMomentumGuide Dec. 27 at 8:21 AM

$CASI Positioning is increasingly shaped by how predictably management executes. Cash discipline will likely dictate investor patience. Any deterioration in traction could reset expectations abruptly. Momentum becomes sustainable only when delivery keeps pace.

0 · Reply

BillionerOfKing Dec. 26 at 5:03 PM

$CASI Current Stock Price: $0.77 Contracts to trade: $2.5 CASI Jan 16 2026 Call Entry: $0.09 Exit: $0.17 ROI: 87% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

Dec 23, 2025, 4:05 PM EST - 22 days ago

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

Dec 11, 2025, 9:00 AM EST - 4 weeks ago

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

Dec 8, 2025, 9:00 AM EST - 5 weeks ago

CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 19, 2025, 9:00 AM EST - 2 months ago

CASI Pharmaceuticals Announces Changes in Board Governance

Nov 14, 2025, 4:05 PM EST - 2 months ago

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

Nov 10, 2025, 4:05 PM EST - 2 months ago

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

Nov 4, 2025, 9:00 AM EST - 2 months ago

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Nov 3, 2025, 9:01 AM EST - 2 months ago

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

Sep 26, 2025, 9:45 AM EDT - 3 months ago

CASI Pharmaceuticals Appoints James Huang to Board of Directors

Sep 8, 2025, 9:00 AM EDT - 4 months ago

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Sep 3, 2025, 9:00 AM EDT - 4 months ago

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 9:00 AM EDT - 4 months ago

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

Aug 29, 2025, 4:05 PM EDT - 4 months ago

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

Aug 28, 2025, 9:00 AM EDT - 4 months ago

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Aug 4, 2025, 9:00 AM EDT - 5 months ago

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

Jul 21, 2025, 4:05 PM EDT - 6 months ago

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

May 19, 2025, 9:00 AM EDT - 8 months ago

CASI Pharmaceuticals Provides Business and Clinical Update

May 16, 2025, 8:00 AM EDT - 8 months ago

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

May 12, 2025, 8:00 AM EDT - 8 months ago

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

May 7, 2025, 8:00 AM EDT - 9 months ago

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

Apr 3, 2025, 8:00 AM EDT - 10 months ago

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

Mar 31, 2025, 8:15 AM EDT - 10 months ago

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

Jan 6, 2025, 8:00 AM EST - 1 year ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

Nov 15, 2024, 8:00 AM EST - 1 year ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Oct 24, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Sep 4, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Aug 16, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Jul 19, 2024, 5:30 PM EDT - 1 year ago

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Jul 8, 2024, 7:30 AM EDT - 1 year ago

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Jun 26, 2024, 4:15 PM EDT - 1 year ago

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

Jun 26, 2024, 4:10 PM EDT - 1 year ago

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

May 15, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

May 14, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

$CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China$

Mar 5, 2024, 7:00 AM EST - 2 years ago

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

Feb 16, 2024, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

Nov 14, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Nov 8, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

Aug 11, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Jul 20, 2023, 8:00 AM EDT - 2 years ago

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

May 17, 2023, 7:35 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

Apr 26, 2023, 9:49 AM EDT - 2 years ago

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Apr 26, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Mar 21, 2023, 4:30 PM EDT - 3 years ago

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Jan 6, 2023, 8:42 AM EST - 3 years ago

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Jan 6, 2023, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

Dec 15, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

BEATOFtheMARKET Jan. 12 at 7:49 PM

$CASI $DRTS $VNET $PYXS Cycle Trading Signal 🔥 app 🔥

0 · Reply

DARKP00L Jan. 12 at 2:18 PM

$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas

0 · Reply

DARKP00L Jan. 12 at 2:08 PM

$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas

0 · Reply

MrDaily Jan. 10 at 1:59 PM

$CASI after the reverse split you’d have to be insane to take a 1.15/share to sell this

0 · Reply

agamemnus Jan. 9 at 5:02 PM

$CASI $1.15 acquisition proposal by biggest shareholder. https://archive.fast-edgar.com/20260109/AUB2K22C8222P2Z2222I2MZZ5H92R2X2N282/

0 · Reply

V9RDPUMA Jan. 9 at 2:07 PM

$CASI Rare disease play

0 · Reply

ClassiTrader Jan. 9 at 12:11 AM

$CASI 💪

0 · Reply

JGroove Jan. 5 at 5:03 PM

$CASI when does the appeal expire?

1 · Reply

MarketMomentumGuide Dec. 27 at 8:21 AM

0 · Reply

BillionerOfKing Dec. 26 at 5:03 PM

0 · Reply

DefendDomain Dec. 26 at 5:59 AM

$CASI Market expectations are recalibrating toward measurable delivery and away from assumptions. Operational consistency must improve quarter by quarter. Capital misallocation remains the key downside risk. Ultimately, this is a case where delivery will decide trajectory.

0 · Reply

JohnTrack Dec. 23 at 9:14 PM

$CASI Extension win, still breathing! https://www.rapidticker.com/news/casi-casi-pharmaceuticals-receives-extension-from-a3c371

0 · Reply

JohnTrack Dec. 11 at 4:18 PM

$CASI better a note than more shares https://www.rapidticker.com/news/casi-casi-pharmaceuticals-announces-up-to-1c795b

0 · Reply

DARKP00L Dec. 11 at 2:35 PM

$CASI 09:12 on Dec. 11 2025 CASI Pharmaceuticals Secures $20M Convertible Note Investment To Fund Phase 1 Renal Transplant Study In China #tradeideas

0 · Reply

JohnTrack Dec. 11 at 2:20 PM

$CASI headline ping recorded https://www.rapidticker.com/news/casi-sec-filing-b9f832

0 · Reply

MarketPlumber Dec. 9 at 6:39 AM

$CASI china scam

0 · Reply

JohnTrack Dec. 8 at 3:38 PM

$CASI watching if bids stack...

0 · Reply

ClassiTrader Dec. 8 at 3:14 PM

$CASI reported postive results needs volume

0 · Reply

JohnTrack Dec. 8 at 2:19 PM

$CASI brief note hit the wire https://www.rapidticker.com/news/casi-casi-pharmaceuticals-announces-results-from-2d0f65

0 · Reply

ClassiTrader Dec. 5 at 7:39 PM

$CASI swinging .90s

0 · Reply

JGroove Nov. 26 at 7:34 PM

$CASI still waiting on that news

1 · Reply

BEATOFtheMARKET Nov. 11 at 2:55 PM

Results List 11/2025 with 13 trading days to go for this list. $CACC $CASI $BTU $BUD $BTDR

0 · Reply

Market Cap	13.28M
Revenue (ttm)	28.54M
Net Income (ttm)	-39.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-137.56%
Debt to Equity Ratio	-0.66

Volume	38,100
Avg Vol	32,438
Day's Range	N/A - N/A
Shares Out	12.30M
Stochastic %K	64%
Beta	0.85
Analysts	Sell
Price Target	$4.00